The companies said they plan to develop multiple mRNA vaccine candidates and hope to develop a single vaccine that will be effective against multiple variants. The vaccine, if approved, may be used to protect people who haven’t been vaccinated or as a booster for people who have been vaccinated.
They said their goal is to get a vaccine candidate approved next year.
GlaxoSmithKline has agreed to support CureVac’s manufacturing of its current COVID-19 vaccine candidate, which is in late-stage clinical trials. GlaxoSmithKline said it will manufacture up to 100 million doses of the vaccine.
Read the full news release here.
More articles on pharmacy:
APhA urges HHS to allow retired pharmacists, pharmacy techs to give vaccines
US COVID-19 vaccinations exceed positive tests for virus, Bloomberg reports
FDA to streamline process to approve vaccines updated for protection against virus variants
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
